Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Emerging Advances for Immunotherapy in Urothelial Cancer

March 9th 2018

Promise of DNA Vaccines in Bladder Cancer

March 9th 2018

Improving Responses to Immunotherapy in Bladder Cancer

March 9th 2018

Ongoing Immuno-Oncology Research in Bladder Cancer

March 9th 2018

A Therapeutic Revolution: Immunotherapy for Bladder Cancer

March 9th 2018

2018 Ushers in New Era of Prostate Cancer Treatment

March 9th 2018

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Renal Cell Carcinoma: An Evolving Treatment Landscape

March 8th 2018

Immunotherapeutic Combinations for mRCC: IMmotion-151

March 8th 2018

Personal Approaches to Treating Brain Metastasis in RCC

March 8th 2018

Metastatic RCC: Selecting Therapy at Recurrence

March 8th 2018

Metastatic Renal Cell Carcinoma: When to Switch Therapy

March 8th 2018

Defining Recurrence in Patients With Metastatic RCC

March 8th 2018

Factors in Selecting Immunotherapy or TKI Inhibition

March 8th 2018

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

March 8th 2018

Evaluating Frontline Systemic Therapy for Metastatic RCC

March 8th 2018

Newly Diagnosed Metastatic RCC: Frontline Therapy

March 8th 2018

Perioperative RCC Treatment: Immunotherapy and Urology

March 8th 2018

RCC: Applying Adjuvant Therapy Data From Clinical Trials

March 8th 2018

Adjuvant Sunitinib's Role in the Treatment of RCC

March 8th 2018

Figlin Discusses Optimizing Expanding Treatment Options in RCC

March 8th 2018

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.